Medicine
SKQ1
SaveA mitochondria-targeted antioxidant (plastoquinone linked to a triphenylphosphonium cation) developed by the Skulachev group in Russia. Studied for age-related diseases and marketed for dry eye.
Quick verdict
Approved in Russia as Visomitin eye drops for dry eye. Systemic longevity applications are based on promising animal data but lack human clinical validation.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Extended lifespan in short-lived fish, fungal, and some mouse models. Mechanism involves selective scavenging of mitochondrial ROS. Phase III clinical data supports efficacy for dry eye disease. Systemic anti-aging trials are in earlier stages. The Skulachev ion concept allows mitochondrial targeting.
Benefits
- Mitochondria-targeted antioxidant with precise subcellular localization
- Lifespan extension in multiple short-lived model organisms
- Approved for dry eye in Russia (Visomitin)
Dosage notes
Ophthalmic: 1 drop in each eye 3 times daily (Visomitin). Systemic dosing for anti-aging is investigational.
Side effects
- Ocular stinging (topical)
- Unknown systemic profile in humans
Who should be cautious
Systemic use in humans is not well-characterized. Ophthalmic use appears safe. Quality and availability outside Russia varies.
What this page cannot tell you
Dry-eye efficacy is supported. Systemic longevity claims rely on animal data and have not been validated in human aging trials.
Leaderboard scores
- Longevity40
Write a review
Sign in to write a review.